Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 8/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309300 | 1.00 | TGFBR1 (0.51) | TGFBR1PIK3CDPIK3CAPI4KAPIK3CG | |
| SCHEMBL3829949 | 0.78 | MYC (0.59) | TGFBR1 | |
| SCHEMBL19638056 | 0.77 | TGFBR1 (0.48) | TGFBR1KDM4EMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1449744 | 0.77 | CDC7 (0.58) | KDM4EGLAMAPTALDH1A1GAA | |
| SCHEMBL15993170 | 0.77 | KDR (0.41) | KDM4EGLANPC1MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL20511964 | 0.76 | KDR (0.40) | KDM4EGLANPC1MAPTRAB9A | |
| SCHEMBL11796387 | 0.76 | TGFBR1 (0.56) | TGFBR1PIK3CDPIK3CAPI4KAPIK3CG | |
| SCHEMBL3737029 | 0.76 | TGFBR1 (0.55) | TGFBR1PIK3CDPIK3CAPI4KAPIK3CG | |
| SCHEMBL31361561 | 0.76 | TGFBR1 (0.55) | TGFBR1PIK3CDPIK3CAPI4KAPIK3CG | |
| SCHEMBL18230478 | 0.75 | CCR1 (0.49) | KDM4EMAPTALDH1A1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110198939-B | Modulators of adenosine A3 receptors | 帕罗生物制药有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-107207445-B | Adenosine A3Modulators of receptors | 帕罗生物制药有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3581572-B1 | ADENOSINE A3 RECEPTOR MODULATORS | PALOBIOFARMA SL (ES) | 2020-11-25 | — | — | EP | disclosed |
| US-10744125-B2 | Adenosine A3 receptor modulators | PALOBIOFARMA, S.L. (ES) | 2020-08-18 | — | — | US | disclosed |
| EP-3248964-B1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA SL (ES) | 2019-07-17 | — | — | EP | disclosed |
| EP-3248964-B1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA SL (ES) | 2019-07-17 | — | — | EP | disclosed |
| US-10238637-B2 | Modulators of the adenosine A3 receptors | PALOBIOFARMA, S.L. (ES) | 2019-03-26 | — | — | US | disclosed |
| US-10238637-B2 | Modulators of the adenosine A3 receptors | PALOBIOFARMA, S.L. (ES) | 2019-03-26 | — | — | US | disclosed |
| US-20180263963-A1 | MODULATORS OF THE ADENOSINE A3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2018-09-20 | — | — | US | disclosed |
| EP-3248964-A1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA S.L. (ES) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016183173-A1 | ANTIPARASITIC COMPOUNDS | Avista Pharma Solutions (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016183173-A1 | ANTIPARASITIC COMPOUNDS | Avista Pharma Solutions (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016116652-A1 | MODULATORS OF THE ADENOSINE A3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2016-07-28 | — | — | WO | disclosed |
| CN-101835766-B | As adenosine A1Receptor antagonist compounds | PALOBIOFARMA SL | 2013-09-25 | — | — | CN | disclosed |
| US-8410282-B2 | Compounds as adenosine A1 receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2013-04-02 | — | — | US | disclosed |
| EP-2197860-B1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA SL (ES) | 2011-05-25 | — | — | EP | disclosed |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2010-12-09 | — | — | US | disclosed |
| CN-101835766-A | As adenosine A1Novel compounds of receptor antagonists | PALOBIOFARMA SL | 2010-09-15 | — | — | CN | disclosed |
| EP-2197860-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | Palobiofarma, S.L. (ES) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009044250-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263963-A1 | MODULATORS OF THE ADENOSINE A3 RECEPTORS | ADORA3, ADORA2A, ADORA1 | TGFBR1 1435/4885PIK3CD 1042/4885PIK3CA 538/4885 |
| US-10744125-B2 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | TGFBR1 2642/4885PIK3CD 973/4885PIK3CA 654/4885 |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | TGFBR1 205/4885PIK3CD 1606/4885PIK3CA 901/4885 |
| US-10238637-B2 | Modulators of the adenosine A3 receptors | ADORA3, ADORA2A, ADORA1 | TGFBR1 1435/4885PIK3CD 1042/4885PIK3CA 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.